Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of astragalus extract

A technology of astragalus extract and astragalus, applied in the field of medicine

Inactive Publication Date: 2016-11-23
THE FIRST AFFILIATED HOSPITAL OF SOOCHOW UNIV
View PDF2 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Astragalus membranaceus, a traditional Chinese medicine, plays an important role in the treatment of CKD. Several literature reports contain Astragalus membranaceus medicinal material in prescriptions. Xie Hongping published "Clinical Observation of Astragalus Injection in the Treatment of Chronic Kidney Disease". The results showed that Astragalus Injection has certain curative effect. The role of delaying the development of CKD, there is no clinical report of Astragalus single medicinal material or extract for clinical oral treatment of CKD

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of astragalus extract
  • Application of astragalus extract
  • Application of astragalus extract

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0063] The preparation of embodiment 1 Astragalus extract

[0064] (1) extraction

[0065] Astragalus decoction pieces 50kg, reflux with 250L of 50% aqueous ethanol to obtain the extract according to the conventional method, filter the extract after concentrating under reduced pressure, and take the filtrate for subsequent use;

[0066] (2) Purification

[0067] The above-mentioned filtrate was subjected to D101 macroporous adsorption resin adsorption, and after removing impurities by water elution, it was eluted with 60% aqueous ethanol, and the 60% ethanol eluate was collected;

[0068] (3) concentrated drying

[0069] The eluate was concentrated under reduced pressure and dried to obtain 8.5 kg of Astragalus extract;

[0070] (4) Content determination

[0071] Astragaloside IV Chromatographic condition C 18(4.6*250mm 5μm); acetonitrile water (32:68) as mobile phase, flow rate 1ml / min, detected by evaporative light scattering detector, flow rate 1.60L / min; evaporation t...

Embodiment 2

[0080] The preparation of embodiment 2 Astragalus extract

[0081] (1) extraction

[0082] Astragalus decoction pieces 50kg, 300L of 70% ethanol to obtain the extract according to the conventional reflux method, the extract is decompressed to recover ethanol, filtered after concentration, and the filtrate is taken for subsequent use;

[0083] (2) Purification

[0084] The above-mentioned filtrate is subjected to AB8 macroporous adsorption resin adsorption, and after removing impurities by water elution, it is eluted with 50% aqueous ethanol, and the 50% ethanol eluate is collected;

[0085] (3) concentrated drying

[0086] The eluate was concentrated under reduced pressure and dried to obtain 7.2 kg of Radix Astragali extract;

[0087] (4) Content determination

[0088] Referring to the content determination method under the item of Example 1, the content of astragaloside IV in the Radix Astragali extract was measured to be 0.92%, and the content of calycosin glucoside was...

Embodiment 3

[0089] The preparation of embodiment 3 Astragalus extract

[0090] (1) extraction

[0091] Astragalus decoction pieces 50kg, reflux with 250L of 30% aqueous ethanol according to conventional methods to obtain the extract, the extract is concentrated under reduced pressure to a relative density of 0.85 at 25°C, filtered, and the filtrate is taken for subsequent use;

[0092] (2) Purification

[0093] The above-mentioned filtrate is subjected to D101 macroporous adsorption resin adsorption, and after removing impurities by water elution, it is eluted with 10% aqueous ethanol, and the 10% ethanol eluate is collected;

[0094] (3) concentrated drying

[0095] The eluate was concentrated under reduced pressure and dried to obtain 8.5 kg of Astragalus extract;

[0096] (4) Content determination

[0097] Astragaloside IV Chromatographic condition C 18 (4.6*250mm 5μm); acetonitrile water (32:68) as mobile phase, flow rate 1ml / min, detected by evaporative light scattering detector...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to the technical field of medicine, in particular to the application of astragalus extract to preparation of NF-kappa B inhibitor. Experiments prove that the astragalus extract can inhibit chronic nephritis NF-kappa B expression and further affect the level of IL-6, TNF-alpha, TGF-beta 1 and MCP-1 and reduce proteinuria. Therefore, the astragalus extract can serve as an active component for inhibiting chronic kidney disease NF-kappa B and be used for preparing drugs for treating chronic kidney disease.

Description

technical field [0001] The invention relates to the technical field of medicine, in particular to the use of an extract of Radix Astragali. Background technique [0002] Chronic kidney disease (Chronickidney disease, CKD) is based on the clinical practice guidelines (K / DOQI) formulated by the American Kidney Foundation (NKF), and the Working Group for Improving the Overall Prognosis of Kidney Diseases (KDIGO) of the International Society of Nephrology clearly puts forward the definition of CKD. Definition: (1) Renal damage (abnormal structure or function of the kidney) for ≥ 3 months, with or without decreased glomerular filtration rate (GFR), abnormal renal pathological examination or renal damage (blood, urine components or imaging Abnormal medical examination); (2) eGFR<60ml·min-1·(1.73m 2 ) -1 ≥3 months, with or without evidence of renal impairment. [0003] Chronic kidney disease is the vast majority of kidney diseases (such as glomerulonephritis, occult nephritis...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K36/481A61P13/12A61P13/00
Inventor 魏明刚
Owner THE FIRST AFFILIATED HOSPITAL OF SOOCHOW UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com